|
RBM27 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.04170005954529E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.58029997368681E-09 |
| Normal-vs-Stage2 |
2.856500E-03 |
| Normal-vs-Stage3 |
9.97830040816439E-10 |
| Normal-vs-Stage4 |
1.29860011632843E-10 |
| Stage1-vs-Stage2 |
2.803800E-01 |
| Stage1-vs-Stage3 |
1.861240E-01 |
| Stage1-vs-Stage4 |
8.523400E-03 |
| Stage2-vs-Stage3 |
8.180400E-02 |
| Stage2-vs-Stage4 |
1.307810E-02 |
| Stage3-vs-Stage4 |
2.311400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.40549851943706E-11 |
| Normal-vs-AfricanAmerican |
1.795430E-03 |
| Normal-vs-Asian |
9.09510000646208E-09 |
| Caucasian-vs-AfricanAmerican |
4.067000E-01 |
| Caucasian-vs-Asian |
3.293800E-01 |
| AfricanAmerican-vs-Asian |
1.370180E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.72580003013445E-09 |
| Normal-vs-Female |
7.7103001761003E-10 |
| Male-vs-Female |
3.893000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.67859999525788E-08 |
| Normal-vs-Age(41-60Yrs) |
2.07069994484499E-09 |
| Normal-vs-Age(61-80Yrs) |
6.00390004379392E-09 |
| Normal-vs-Age(81-100Yrs) |
1.833970E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.893400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.651600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.513200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.217000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.848600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.211800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.654500E-02 |
| Classical-VS-Follicular |
6.852400E-01 |
| Classical-VS-Other |
2.255800E-01 |
| Classical-VS-Normal |
1.09909999990165E-08 |
| Tall-VS-Follicular |
2.080000E-01 |
| Tall-VS-Other |
6.825600E-01 |
| Tall-VS-Normal |
6.79520000268496E-08 |
| Follicular-VS-Other |
3.120000E-01 |
| Follicular-VS-Normal |
8.47010000026849E-07 |
| Other-VS-Normal |
1.895080E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.68380001239899E-09 |
| Normal-vs-N1 |
3.02610003721782E-09 |
| N0-vs-N1 |
1.180960E-01 |
|
|
